Additionally, the 36-month beta value for IMVT is 0.64. There are mixed opinions on the stock, with 11 analysts rating it as a “buy,” 4 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for IMVT is 59.16M and currently, short sellers hold a 21.69% ratio of that float. The average trading volume of IMVT on January 30, 2025 was 962.11K shares.
IMVT) stock’s latest price update
Immunovant Inc (NASDAQ: IMVT)’s stock price has plunge by -1.09relation to previous closing price of 22.03. Nevertheless, the company has seen a -6.20% plunge in its stock price over the last five trading sessions. prnewswire.com reported 2025-01-24 that NEW YORK, Jan. 24, 2025 /PRNewswire/ — Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Immunovant, Inc. (NASDAQ: IMVT) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.
IMVT’s Market Performance
Immunovant Inc (IMVT) has seen a -6.20% fall in stock performance for the week, with a -15.31% decline in the past month and a -27.90% plunge in the past quarter. The volatility ratio for the week is 3.66%, and the volatility levels for the past 30 days are at 4.87% for IMVT. The simple moving average for the past 20 days is -7.71% for IMVT’s stock, with a -22.72% simple moving average for the past 200 days.
Analysts’ Opinion of IMVT
Raymond James, on the other hand, stated in their research note that they expect to see IMVT reach a price target of $36. The rating they have provided for IMVT stocks is “Outperform” according to the report published on October 10th, 2024.
Oppenheimer gave a rating of “Outperform” to IMVT, setting the target price at $53 in the report published on October 09th of the previous year.
IMVT Trading at -15.31% from the 50-Day Moving Average
After a stumble in the market that brought IMVT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -44.91% of loss for the given period.
Volatility was left at 4.87%, however, over the last 30 days, the volatility rate increased by 3.66%, as shares sank -11.02% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -24.60% lower at present.
During the last 5 trading sessions, IMVT fell by -6.20%, which changed the moving average for the period of 200-days by -29.07% in comparison to the 20-day moving average, which settled at $23.61. In addition, Immunovant Inc saw -12.03% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IMVT starting from Stout Jay S, who sale 2,195 shares at the price of $23.59 back on Jan 22 ’25. After this action, Stout Jay S now owns 139,991 shares of Immunovant Inc, valued at $51,780 using the latest closing price.
Geffner Michael, the Chief Medical Officer of Immunovant Inc, sale 2,657 shares at $23.59 during a trade that took place back on Jan 22 ’25, which means that Geffner Michael is holding 132,314 shares at $62,679 based on the most recent closing price.
Stock Fundamentals for IMVT
Current profitability levels for the company are sitting at:
- -228.29 for the present operating margin
- 0.87 for the gross margin
The net margin for Immunovant Inc stands at -215.34. The total capital return value is set at -0.76. Equity return is now at value -92.17, with -79.97 for asset returns.
Based on Immunovant Inc (IMVT), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -5779.64.
Currently, EBITDA for the company is -269.98 million with net debt to EBITDA at 1.34. When we switch over and look at the enterprise to sales, we see a ratio of 2151.83. The receivables turnover for the company is 0.8for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.61.
Conclusion
In conclusion, Immunovant Inc (IMVT) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
